| Document |
Document Title |
|
WO/2006/108678A2 |
S-Adenosyl-L-methionine analogs of formula (I) wherein R comprises a carbon-carbon double bond, carbon-oxygen double bond, carbon-sulfur double bond, carbon-nitrogen double bond, a carbon-carbon triple bond, carbon-nitrogen triple bond o...
|
|
WO/2006/105529A1 |
The present invention is directed to a processes for the synthesis of trans isomer of 4,6-disubstituted-tetrahydro-furo, thieno, pyrrolo and cyclopenta-[3,4][l ,3]dioxoles (Formula I). The process comprises the steps of: (a) obtaining a ...
|
|
WO/2006/105440A2 |
Provided herein are sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders incl...
|
|
WO/2006/100647A1 |
The present invention relates to the formation of hydrogels based on guanosine hydrazide derivatives in the presence of cations. The hydrogels can be used as a carrier/delivery system for biologically active substances such as flavors, f...
|
|
WO/2006/100439A1 |
Phosphoramidate derivatives of nucleoside compounds such as cladribine, isocladribine, fludaribine and clofarabine have enhanced therapeutic potency in homo sapiens, in particular, enhanced potency with respect to a cancer such as leukae...
|
|
WO/2006/100087A2 |
A pharmaceutical composition and granulates, prepared by a wet granulation process. The pharmaceutical composition and granulates contain a therapeutic compound, e.g., the 3'-L-valine ester of β-D-2'-C-methyl-riboguranosyl cytidine valo...
|
|
WO/2006/102594A1 |
Disclosed are prodrug compounds of Formula I, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus.
|
|
WO/2006/101911A1 |
An agent for inhibiting translesion DNA replication comprises a non-natural adenine ribose analog represented by those as set forth in Figure 1.
|
|
WO/2006/098761A2 |
The invention provides purified 18,21-didehydro-18,21-dideoxo-18,21-dihydroxy-geldanamycin derivatives, pharmaceutically acceptable salts thereof and prodrugs thereof that are potent Hsp90 binding agents that are useful for the treatment...
|
|
WO/2006/097260A1 |
Compounds of (I), or stereoisomers or pharmaceutically acceptable salts thereof, where W, R1, R2, R3 and R4 have the meanings as indicated in the specification, are useful for treating conditions mediated by activation of the adenosine A...
|
|
WO/2006/098444A1 |
A fluoro derivative can be produced by reacting a hydroxy derivative with sulfuryl fluoride (SO2F2) in the presence of an organic base or in the presence of an organic base and a salt or complex composed of an organic base and hydrogen f...
|
|
WO/2006/097320A2 |
The invention relates to the structure, production and use of modified nucleotide and nucleoside building blocks, ( nuc-macromolecules ).
|
|
WO/2006/095739A1 |
A process for deblocking the 2'-hydroxyl groups of ribonucleosides, characterized by reacting a ribonucleoside derivative represented by the general formula (I) wherein the 2'-hydroxyl group is blocked: [Chemical formula 1] (I) [wherein ...
|
|
WO/2006/096757A2 |
Compounds for modulating RecA protein activity are provided. In some embodiments, the compounds modulate RecA activity by interfering with assembly of monomeric RecA protein subunits into a nucleoprotein filament. In some embodiments, th...
|
|
WO/2006/095740A1 |
Disclosed is a method for synthesizing a nucleic acid which is characterized by comprising a step wherein a compound represented by the general formula (III) below is obtained by reacting a compound represented by the general formula (I)...
|
|
WO/2006/095831A1 |
Disclosed is a technique for stably immobilizing a probe on a carrier. For achieving the aim, a linker compound represented by the formula (2) below is used in this invention. (In the formula, A represents a hydrogen atom, an other subst...
|
|
WO/2006/095830A1 |
The present invention aims to provide a technique for stably immobilizing a probe on a carrier. For achieving this aim, a linker compound represented by the formula (1) below is used in this invention. [Chemical formula 9] (1) (In the fo...
|
|
WO/2006/095359A1 |
The invention describes the synthesis of hereto unreported 2-deoxy-2,2-difluoro-D-ribofuranose-3,5-di-(aroyl) derivative of formula-Vb, where in R=;CH3,CI,NO2 and its conversion to Gemcitabine HCl of formula-I, an anti cancer product.
|
|
WO/2006/093986A1 |
This invention is directed to novel compounds that are useful in the viral infections in mammals, mediated at least in part by a vims in the Flaviviridae family of viruses. In one of its composition aspects, the present invention is dire...
|
|
WO/2006/093987A1 |
Disclosed are tricyclic nucleoside compounds of formula (I), and methods thereof for treating viral infections mediated at least in part by a Flaviviridae family virus.
|
|
WO/2006/092808A1 |
A highly stereoselective, simple and economical glycosylation process for preparation of β-anomer enriched 21-deoxy-21,21-D-ribofuranosyl difluoronucleosides of formula (II), and physiologically acceptable slats thereof, in particular, ...
|
|
WO/2006/093157A1 |
[PROBLEMS] To provide an oligonucleotide derivative which can be used in a DNA probe with no fear of being fallen out from a substrate. [MEANS FOR SOLVING PROBLEMS] The oligonucleotide derivative is represented by the general formula (1)...
|
|
WO/2006/093110A1 |
8-Nitroguanosine-3’,5’-cyclic monophosphate represented by the formula below, and a pharmaceutical composition comprising 8-nitroguanosine-3’,5’-cyclic monophosphate as an active ingredient, particularly a protein kinase G activa...
|
|
WO/2006/090029A1 |
The invention concerns a 2',2'-difluoro-2'-deoxycytidine derivative of general formula (I), wherein: R1, R2 and R3, identical or different, represent independently of one another, a hydrogen atom or an at least C18 hydrocarbon acyl radic...
|
|
WO2006060614A9 |
The present invention provides a process for the preparation of pimecrolimus from ascomycin in which ascomycin is reacted with a conversion reagent that converts ascomycin to its activated derivative at C-32. The activated ascomycin is t...
|
|
WO/2006/084067A2 |
The specification discloses quenchers of excited state energy, probes and other conjugates comprising the same, and methods for their use. The quenchers of excited state energy have a structure comprising at least one reactive functional...
|
|
WO/2006/081665A1 |
The present invention is directed to purine nucleoside analogs of the general Formula (I), or tautomers thereof, physiologically acceptable salts, solvents and physiologically functional derivatives thereof, and pharmaceutical compositio...
|
|
WO/2006/080421A1 |
Disclosed is a compound represented by the following formula (I). [Chemical formula 1] (I) (In the formula, R1, R2, R3 and R4 independently represent a hydrogen atom, an optionally substituted C1-C6 alkyl group, an optionally substituted...
|
|
WO/2006/080509A1 |
A novel pyrimidine nucleoside compound, or its salt, of the general formula: (1) wherein one of X and Y is a cyano while the other is a hydrogen atom; and one of R1 and R2 is a hydrogen atom, a carbonyl having an alkyl monosubstituted wi...
|
|
WO/2006/077816A1 |
The invention relates to a novel imidazo[4,5-b]pyridine derivative compound represented by the formula (I) and a pharmaceutically acceptable salt thereof. The invention also relates to a method of producing the compound. The invention fu...
|
|
WO/2006/078752A2 |
The invention relates to the inhibition of DNA methyltransferase isoforms DNMT1 and DNMT3b2. The invention provides compounds and methods for inhibiting DNMT1 and DNMT3b2.
|
|
WO/2006/075993A2 |
Disclosed are adenosine derivatives, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus.
|
|
WO/2006/076102A2 |
The present invention provides fluorescent nucleoside analogs with conjugated membered heterocycles, including furan and thiophene. The fluorescent nucleoside analogs maintain structural similarity to naturally occurring nucleoside bases...
|
|
WO/2006/074416A1 |
The present invention provides a method for increasing the efficacy of antifolates which act via inhibition of dihydrofolate reductase (DHFR). The method comprises the steps of administration of 5-amino-4-imidazolecarboxarnide riboside (...
|
|
WO/2006/070985A1 |
This invention relates to an improved method for stereoselectively preparing 2´-deoxy-2´,2´-difluorocytidine of formula (I), which comprises the steps of reacting a 1-halo ribofuranose compound of formula (III) with a nucleobase of fo...
|
|
WO/2006/071090A1 |
This invention relates to an improved method for stereoselectively preparing 2¢¥-deoxy-2¢¥,2¢¥-difluorocytidine of formula (I), which comprises the steps of reacting a 1-halo ribofuranose compound of formula (III) with a nucleobase...
|
|
WO/2006/066439A2 |
Nucleic acid sequence analogues, in particular tRNA analogues comprising in the place of a 3'-terminal adenosine a 3'-terminal 2'-deoxy-2'-thioadenosine are able to react site-specifically with weakly activated amino acid derivatives (e....
|
|
WO/2006/066074A2 |
Methods and compositions are provided for treating lung diseases, including but not limited to infections and small cell and non-small cell lung cancer, by conjugating a drug of interest to glycerol ethers or lycerol phosphate ethers.
|
|
WO/2006/065525A1 |
The present invention relates to novel amide prodrugs of gemcitabine, compositions thereof and methods for using.
|
|
WO/2006/063717A2 |
The present invention concerns methods of polymerase independent template directed elongation of polynucleotides, nucleotide building blocks used in these methods as well as the use of the methods and building blocks for the determinatio...
|
|
WO/2006/062434A1 |
The invention relates to molecular biology, virology and medicine, in particular to novel 3'azido-3'-dezoxythymidine-phosphonates of general formula (I), wherein R is alkyl groups including groups containing halogen atoms, carboxy, hydro...
|
|
WO/2006/063105A1 |
A stereoselective process for the preparation of a 2’,2’-difluronucleoside is provided. In the process, a protected 2’,2’-difluorofuranose is coupled with a base selected from the group consisting of pyrimidine and purine derivat...
|
|
WO/2006/060617A1 |
The present invention provides novel crystalline forms of ascomycin as well as processes for the preparation thereof and pharmaceutical compositions comprising such crystalline forms of ascomycin.
|
|
WO/2006/060615A1 |
An amorphous pimecrolimus and processes for providing an amorphous pimecrolimus are provided.
|
|
WO/2006/058796A2 |
The invention relates to a method for making osyl and hexoses derivatives of formula (1), especially 2-fluoro-2-deoxy derivatives, wherein R is a nucleoside such as adenosine, cytidine, guanosine, uridine and deoxy analogs such as 2-deox...
|
|
WO/2006/060616A1 |
The present invention provides processes for crystallization of macrolides, specifically pimecrolimus and tacrolimus.
|
|
WO/2006/045616A2 |
The invention relates to β-L-N4-hydroxycytosine nucleo-sides, pharmaceutical agents comprising same, and to the use of said β-L-N4-hydroxycytosine nucleosides and pharmaceutical agents in the prophylaxis or therapy of an infection caus...
|
|
WO/2006/040111A2 |
A process for the production of 33-Epi-33-chloro-FR 520 in one step from FR520 wherein protecting groups are avoided.
|
|
WO/2006/040558A1 |
This invention relates to compounds of Formula (I): and their use in the treatment of bacterial infections.
|
|
WO2006015357A9 |
The invention provides compounds having the following general formula (I): wherein X, R
|
